High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers

Respirology

Volumn 19, Issue 2, 2014, Pages 253-261

  Ko, Hsin Kuo ^a,b   Hsu, Wen Hu ^b   Hsieh, Chih Cheng ^a,b   Lien, Te Cheng ^b   Lee, Tzong Shyuan ^a   Kou, Yu Ru ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

blood; chronic obstructive pulmonary disease; gene expression; high mobility group box 1; lung function impairment

Indexed keywords

BRONCHODILATING AGENT; HIGH MOBILITY GROUP B1 PROTEIN;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FUNCTION; LUNG PARENCHYMA; LUNG SURGERY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMOKING; ADVERSE EFFECTS; BIOSYNTHESIS; LUNG; METABOLISM; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84892614790     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12209     Document Type: Article

References (33)

1. Mannino DM, Buist AS,. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
2. Celli BR, Halbert RJ, Nordyke RJ, Schau B,. Airway obstruction in never smokers: results from the Third National Health and Nutrition Examination Survey. Am. J. Med. 2005; 118: 1364-1372.
3. Behrendt CE,. Mild to moderate-to-severe COPD in nonsmokers: distinct demographic profiles. Chest 2005; 128: 1239-1244.
4. Lamprecht B, Schirnhofer L, Kaiser B, Buist S, Studnicka M,. Non-reversible airway obstruction in never smokers: results from the Austrian BOLD study. Respir. Med. 2008; 102: 1833-1838.
5. Bridevaux PO, Probst-Hensch NM, Schindler C, Curjuric I, Felber Dietrich D, Braendli O, Brutsche M, Burdet L, Frey M, Gerbase MW, et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur. Respir. J. 2010; 36: 1259-1269.
6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management, and prevention of COPD. [Accessed 1 Jan 2013.] Available from URL: http://www.goldcopd.com
7. de Torres JP, Cordoba-Lanus E, Lõpez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C,. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006; 27: 902-907.
8. Hill AT, Bayley D, Stockley RA,. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am. J. Respir. Crit. Care Med. 1999; 160: 893-898.
9. Yamamoto C, Yoneda T, Yoshikawa M, Fu A, Tokurama T, Tsukaguchi K, Narita N,. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.
10. Keatings VM, Collins PD, Scott DM, Barnes PJ,. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996; 153: 530-534.
11. Bhowmik A, Seemungal TAR, Sapsford RJ, Wedzicha JA,. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
12. Vignola AM, Chanez P, Chiappara G, Merendino A, Pace E, Rizzo A, la Rocca AM, Bellia V, Bonsignore G, Bousquet J,. Transforming growth factor-beta expression in mucosal biopsies in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 1997; 156: 591-599.
13. Seemungal TA, Lun JC, Davis G, Neblett C, Chinyepi N, Dookhan C, Drakes S, Mandeville E, Nana F, Setlhake S, et al. Plasma homocysteine is elevated in COPD patients and is related to COPD severity. Int. J. Chron Obstruct. Pulm. Dis. 2007; 2: 313-321.
14. Goodwin GH, Sanders C, Johns EW,. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 1973; 38: 14-19.
15. Lotze MT, Tracey KJ,. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 2005; 5: 331-342.
16. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
17. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susaria SM, Ulloa L, Wang H, DiRaimo R, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Nati Acad. Sci. U.S.A. 2004; 101: 296-301.
18. Sundén-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ,. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit. Care Med. 2005; 33: 564-573.
19. Kim JY, Park JS, Strassheim D, Douglas I, Diaz del Valle F, Asehnoune K, Mitra S, Kwak SH, Yamada S, Maruyama I, et al. HMGB1 contributes to the development of acute lung injury after hemorrhage. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: L958-965.
20. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ,. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 2000; 165: 2950-2954.
21. Ueno H, Matsuda T, Hashioto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Respir. Crit. Care Med. 2004; 170: 1310-1316.
22. Lin X, Yang H, Sakuragi T, Hu M, Mantell LL, Hayashi S, Al-Abed Y, Tracey KJ, Ulloa L, Miller EJ,. Alpha-chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 289: L583-590.
23. Ogawa EN, Ishizaka A, Tasaka S, Koh H, Ueno H, Amaya F, Ebina M, Yamada S, Funakoshi Y, Soejima J, et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am. J. Respir. Crit. Care Med. 2006; 174: 400-407.
24. Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am. J. Respir. Crit. Care Med. 2008; 178: 822-831.
25. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, Dombret MC, Sims GP, Kolbeck R, Coyle AJ, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181: 917-927.
26. Anthonien NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA,. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
27. Kanazawa H, Tochino Y, Asai K, Ichimaru Y, Watanabe T, Hirata K,. Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD. Eur. J. Clin. Invest. 2012; 42: 419-426.
28. Andersson U, Tracey KJ,. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 2011; 29: 139-162.
29. Bianchi ME,. HMGB1 loves company. J. Leukoc. Biol. 2009; 86: 573-576.
30. Sims GP, Rowe DC, Rietdiijk ST, Herbest R, Coyle AJ,. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol. 2010; 28: 367-388.
31. Schierbeck J, Wähämaa H, Andersson U, Harris HE,. Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol. Med. 2010; 16: 343-351.
32. Tang D, Kang R, Zeh HJ, Lotze MT,. High-Mobility Group Box 1, oxidative stress, and disease. Antioxid. Redox Signal. 2011; 14: 1315-1335.
33. Shang GH, Jia CQ, Tian H, Xiao W, Li Y, Wang AH, Dong L, Lin DJ,. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir. Med. 2009; 102: 1949-1953.